Journal of Cachexia, Sarcopenia and Muscle · Nov 17, 2026

Semaglutide‐Induced Weight Loss Does Not Impair Muscle Function and Improves Endurance Running Capacity in Obese Mice

By Minderis P, Cesanelli L, Sviderskis M et al.

Background: Semaglutide, a member of the glucagon‐like peptide‐1 receptor agonists, induces substantial weight loss, primarily through appetite suppression and reduced energy intake. In addition to fat mass reduction, a considerable loss of lean body mass is also observed. How these effects compare to conventional caloric restriction is unclear. The aim of the current study was to compare the effects of semaglutide injections and energy‐matched caloric restriction on skeletal muscle mass, function and exercise capacity. Methods: An 8‐month‐old high‐fat diet‐induced obese male C57BL/6J mice were pair‐fed ( n = 14), with one receiving semaglutide injections (SEMA; 30 μg/kg/day) and the other undergoing energy‐matched caloric restriction (CR; sham PBS injections) for 28 days. A group of obese mice ( n = 12) continued unrestricted high‐fat feeding and served as controls (CON). Body mass and energy intake were monitored daily. During the final week, exercise capacity was assessed using a progressive treadmill test with oxygen consumption and lactate measurements. At study completion, mice were euthanized, and slow‐ and fast‐twitch muscles (soleus [SOL] and extensor digitorum longus [EDL]) were dissected, weighed and used for ex vivo assessment of mechanical and contractile properties. Results: Despite similar energy intake, SEMA mice lost more body mass than CR mice (20.9 ± 4.9 vs. 14.8% ± 5.8%, p < 0.01). Both groups exhibited lower SOL muscle mass compared with CON (10.0 ± 0.7 mg; SEMA: 9.1 ± 0.8 mg, p < 0.01; CR: 9.4 ± 0.7 mg, p < 0.05), whereas EDL muscle mass was not significantly different. During the treadmill test, SEMA mice displayed higher relative VO ₂ peak (43.4 ± 3.0 mL/min/ kg 0.75 ) compared with CR (40.8 ± 2.6 mL/min/kg 0.75 , p < 0.05) and CON (38.6 ± 2.69 mL/min/kg 0.75 , p < 0.001), together with advantages in running distance and maximal running speed, which were largely attributable to lower body mass. SOL and EDL force, normalized to muscle mass and PCSA, did not differ between groups (SOL: 21.2 ± 2.8 N/g and 22.4 ± 3.1 N/cm ² [SEMA], 20.8 ± 2.4 N/g and 21.7 ± 2.5 N/cm ² [CR], 19.7 ± 3.5 N/g and 20.4 ± 3.7 N/cm ² [CON]; EDL: 22.8 ± 2.2 N/g and 17.0 ± 2.0 N/cm ² [SEMA], 24.5 ± 2.5 N/g and 18.2 ± 2.0 N/cm ² [CR], 22.9 ± 2.1 N/g and 16.8 ± 1.8 N/cm ² [CON]). Muscle contraction and relaxation kinetics as well as stretched induced hysteresis and relaxation were similar across groups. Conclusions: In obese mice, semaglutide induces greater weight loss but similar muscle loss than energy‐matched caloric restriction, while improving aerobic endurance without compromising skeletal muscle function.

doi.org/10.1002/jcsm.70427Open accessPubMed 43041190Interventions

AgingResearch.News